On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Nitrosamines Found in Sertraline, Telmisartan Generics; Shipments to Continue
Towa Pharmaceutical and Feldsenf Pharma reported on November 10 that nitrosamine impurities have been detected in their respective generic versions of antidepressant Jzoloft (sertraline) and antihypertensive Micardis (telmisartan). Both companies will continue shipments and distribution. In notices to healthcare professionals,…
To read the full story
Related Article
- Nitrosamine Impurities Reported for Generic Telmisartan; No Recalls Planned
November 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
- Nitrosamine Detected in Viatris’ Jzoloft OD Tablets
June 4, 2026
BUSINESS
- Japan Pharma Market Put at 13 Trillion Yen in FY2031, Growth to Slow: IQVIA
November 11, 2026
- Kyorin Targets 10 Billion Yen-Plus Assets in Licensing Push
November 11, 2026
- Nitrosamines Found in Sertraline, Telmisartan Generics; Shipments to Continue
November 11, 2026
- Shionogi Secures 300 Billion Yen Bridge Loan for IntraBio Buyout
November 11, 2026
- Sanofi Japan Bets on Beyfortus Track Record with NIP Inclusion in Sight
November 11, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…